Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

OBJECTIVE: Somapacitan is a long‐acting, reversible albumin‐binding growth hormone (GH) derivative in development. This study aimed to evaluate the safety and efficacy of once‐weekly somapacitan versus daily GH over 52 weeks in Japanese patients with adult growth hormone deficiency (AGHD). DESIGN: P...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Endocrinol (Oxf)
Glavni autori: Otsuka, Fumio, Takahashi, Yutaka, Tahara, Shigeyuki, Ogawa, Yoshihisa, Højby Rasmussen, Michael, Takano, Koji
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689735/
https://ncbi.nlm.nih.gov/pubmed/32603494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cen.14273
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items